translation agency

BBC News
Pharmasset Presents Results of 4-Week Combination Study of R7128

April 25, 2008
- 85% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) -

- Safety and tolerability comparable to placebo administered with Pegasys plus Copegus -

- EASL presentation available on Pharmasset website -

- Conference call scheduled for Friday, April 25, 2008 at 1:00 PM ET (US) and 7:00 PM CEST (Milan) -

PRINCETON, N.J. and MILAN, Italy, April 25 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (NASDAQ:VRUS) announces the results of a 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in 50 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche. The results of this study were presented today at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) being held from April 23-27, 2008 in Milan, Italy.



www.aegis.org